Bone complications: an increasing risk in patients with prostate cancer.
D000726:Androgen Antagonists / Q000009:adverse effects* / Q000627:therapeutic use; D050071:Bone Density Conservation Agents / Q000627:therapeutic use*; D001859:Bone Neoplasms / Q000188:drug therapy* / Q000556:secondary; D004164:Diphosphonates / Q000627:therapeutic use*; D006801:Humans; D008297:Male; D010024:Osteoporosis / Q000139:chemically induced / Q000188:drug therapy*; D011471:Prostatic Neoplasms / Q000188:drug therapy* / Q000473:pathology; D012306:Risk
D000726:Androgen Antagonists; D050071:Bone Density Conservation Agents; D004164:Diphosphonates